These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 16360354)

  • 21. Sirolimus- versus paclitaxel-eluting stents for the treatment of coronary bifurcations results: from the COBIS (Coronary Bifurcation Stenting) Registry.
    Song YB; Hahn JY; Choi SH; Choi JH; Lee SH; Jeong MH; Kim HS; Seong IW; Yang JY; Rha SW; Jang Y; Yoon JH; Tahk SJ; Seung KB; Park SJ; Gwon HC
    J Am Coll Cardiol; 2010 Apr; 55(16):1743-50. PubMed ID: 20394879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term clinical outcomes and thrombosis rates of sirolimus-eluting versus paclitaxel-eluting stents in an unselected population with coronary artery disease (REWARDS registry).
    Waksman R; Buch AN; Torguson R; Xue Z; Smith K; Javaid A; Chu WW; Satler LF; Kent KM; Pichard AD;
    Am J Cardiol; 2007 Jul; 100(1):45-51. PubMed ID: 17599439
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: comparison with bare-metal stent implantation.
    Gao RL; Xu B; Chen JL; Yang YJ; Qiao SB; Li JJ; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J
    Am Heart J; 2008 Mar; 155(3):553-61. PubMed ID: 18294496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and angiographic outcomes after placement of multiple overlapping drug-eluting stents in diffuse coronary lesions.
    Lee CW; Park KH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Am J Cardiol; 2006 Oct; 98(7):918-22. PubMed ID: 16996874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
    Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
    JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One-year outcomes from the TAXUS express stent versus cypher stent.
    Mayor M; Malik AZ; Minor RJ; Deshpande MC; Strauss WE; Maloney TH; Baim DS; O'Neill W; Kandzari DE
    Am J Cardiol; 2009 Apr; 103(7):930-6. PubMed ID: 19327418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymer-free sirolimus-eluting versus polymer-based paclitaxel-eluting stents: an individual patient data analysis of randomized trials.
    Cassese S; Desch S; Kastrati A; Byrne RA; King L; Tada T; Lauer B; Schömig A; Thiele H; Pache J
    Rev Esp Cardiol (Engl Ed); 2013 Jun; 66(6):435-42. PubMed ID: 24776045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized comparison of sirolimus- versus Paclitaxel-eluting stent implantation in patients with diabetes mellitus.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Hong MK; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ
    J Am Coll Cardiol; 2008 Aug; 52(9):727-33. PubMed ID: 18718419
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of sirolimus versus paclitaxel eluting stents for treatment of coronary in-stent restenosis.
    Airoldi F; Briguori C; Iakovou I; Stankovic G; Biondi-Zoccai G; Carlino M; Chieffo A; Montorfano M; Cosgrave J; Michev I; Rogacka R; Sangiorgi GM; Colombo A
    Am J Cardiol; 2006 Apr; 97(8):1182-7. PubMed ID: 16616023
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.
    Harjai KJ; Kondareddy S; Pinkosky B; Harjai N; Orshaw P; Boura J
    J Interv Cardiol; 2013 Apr; 26(2):153-62. PubMed ID: 23363439
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparable clinical outcomes with paclitaxel- and sirolimus-eluting stents in unrestricted contemporary practice.
    Cosgrave J; Melzi G; Corbett S; Biondi-Zoccai GG; Agostoni P; Babic R; Airoldi F; Chieffo A; Sangiorgi GM; Montorfano M; Michev I; Carlino M; Colombo A
    J Am Coll Cardiol; 2007 Jun; 49(24):2320-8. PubMed ID: 17572247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Dangas GD; Serruys PW; Kereiakes DJ; Hermiller J; Rizvi A; Newman W; Sudhir K; Smith RS; Cao S; Theodoropoulos K; Cutlip DE; Lansky AJ; Stone GW
    JACC Cardiovasc Interv; 2013 Sep; 6(9):914-22. PubMed ID: 24050859
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictive factors of cardiac events after implantation of sirolimus-eluting stents for treatment of in-stent restenosis.
    Le Feuvre C; Montalescot G; Rosey G; Collet JP; Beygui F; Choussat R; Gelft G; Monségu J; Ohanessian A; Spaulding C; Drobinski G; Metzger JP
    Int J Cardiol; 2006 May; 109(2):207-12. PubMed ID: 15993962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One-year clinical outcome after coronary stenting of very small vessels using 2.25 mm sirolimus- and paclitaxel-eluting stents: a comparison between the RESEARCH and T-SEARCH registries.
    Rodriguez-Granillo GA; Valgimigli M; Garcia-Garcia HM; Ong AT; Aoki J; van Mieghem CA; Tsuchida K; Sianos G; McFadden E; van der Giessen WJ; van Domburg R; de Feyter P; Serruys PW
    J Invasive Cardiol; 2005 Aug; 17(8):409-12. PubMed ID: 16079445
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries).
    Daemen J; Tanimoto S; García-García HM; Kukreja N; van de Sande M; Sianos G; de Jaegere PP; van Domburg RT; Serruys PW
    Am J Cardiol; 2007 Apr; 99(8):1027-32. PubMed ID: 17437722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of coronary bifurcation lesions with drug-eluting stents: insights from the first phase of the prospective multicenter german drug-eluting stent registry.
    Abdel-Wahab M; Nienaber CA; Mostafa AE; Ferenc M; Silber S; Sabin G; Tebbe U; Akin I; Hochadel M; Senges J; Kuck KH; Richardt G;
    J Interv Cardiol; 2012 Aug; 25(4):344-52. PubMed ID: 22409587
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of six-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the RESEARCH (rapamycin-eluting stent evaluated at Rotterdam cardiology hospital) and T-SEARCH (taxus stent evaluated at Rotterdam cardiology hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta S; Daemen J; Gaspersz M; van Geuns RJ; van der Giessen W; van Domburg R; Serruys P
    J Invasive Cardiol; 2011 Aug; 23(8):336-41. PubMed ID: 21828397
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Mahaffey KW; Cutlip DE; Fitzgerald PJ; Sood P; Su X; Lansky AJ;
    JAMA; 2008 Apr; 299(16):1903-13. PubMed ID: 18430909
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation.
    Ong AT; Hoye A; Aoki J; van Mieghem CA; Rodriguez Granillo GA; Sonnenschein K; Regar E; McFadden EP; Sianos G; van der Giessen WJ; de Jaegere PP; de Feyter P; van Domburg RT; Serruys PW
    J Am Coll Cardiol; 2005 Mar; 45(6):947-53. PubMed ID: 15766834
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.